Linkage to hepatitis C treatment in two opioid substitution treatment units in Gothenburg, Sweden: a retrospective cohort study

Table 1 Patient characteristics at baseline and end of study

	Overall cohort (n = 225)
	Baseline	End of study	P value^d
Sex (M/F)	214/11	-
Age (Years, mean (SD))	44.5 (9.5)	-
anti-HCV^a,b ( ±)	134/88	133/91	n.s
HCV RNA/Ag ( ±)	90/44	65/68	0.003
Patients attending Clinic of Infectious Diseases^c (yes/no)	44/46	34/31	n.s
Time to last HCV-test, years (median, IQR)	1.2 (0.3–4.0)	1.3 (0.8–1.8)	0.005

SD Standard deviation, HCV Hepatitis C virus, Ag Antigen, IQR Interquartile range, n.s. Not significant
^amissing data baseline n = 3, end of study n = 1
^bone patient was anti-hcv negative on new testing
^cPatients who had attended a visit at the Clinic of Infectious diseases during the past year or a had new appointment scheduled the following year
^dTime to last HCV-test—Wilcoxon signed-rank test, all other comparisons—Chi-square test

ISSN: 1747-597X